accentia biopharmaceuticals
(ABPI:OTC US)
accentia biopharmaceuticals (ABPI) Snapshot
|
Open
$0.0095
|
Previous Close
$0.0095
|
|
|
Day High
$0.01
|
Day Low
$0.0095
|
|
|
52 Week High
07/24/12 - $0.28
|
52 Week Low
06/13/13 - $0.0051
|
|
|
Market Cap
897.6K
|
Average Volume 10 Days
374.4K
|
|
|
EPS TTM
$-0.25
|
Shares Outstanding
89.8M
|
|
|
EX-Date
--
|
P/E TM
--
|
|
|
Dividend
--
|
Dividend Yield
--
|
Related News
accentia biopharmaceuticals (ABPI) Related Businessweek News
No Related Businessweek News Foundaccentia biopharmaceuticals (ABPI) Details
Accentia Biopharmaceuticals, Inc., a biotechnology company, primarily engages in the discovery, development, and commercialization of immunotherapies to treat autoimmune related diseases and cancer in the United States. The company develops Cyrevia as a system of care for various autoimmune diseases; BiovaxID as a personalized therapeutic cancer vaccine to treat non-Hodgkin’s lymphoma, follicular lymphoma, mantle cell lymphoma, and other B-cell cancers; and SinuNasal lavage system as a medical device for chronic sinusitis. It also manufactures and sells a range of cell culture systems used for the production cell culture products, including HF Primer, a cell culture system for producing small, research, and development quantities of cell culture products from mammalian cell lines; Multi-6 for producing six monoclonal antibodies; AutovaxID, an automated cell culture system for production of personalized cell-based treatments and various additional vaccines; Acusyst-miniMax system, which offers two single-use disposables options to meet various production requirements; Acusyst-Maximizer, a system for process development and routine productions; and Acusyst-Xcellerator, a production-scale cell culture system. In addition, the company manufactures mammalian cell culture products such as, whole cells, recombinant and secreted proteins, and monoclonal antibodies, as well as provides related services in developing cell production process protocols, cell line optimization, cell culture production optimization, media evaluation, and other related services. Further, it sells hollow fiber bioreactors, cultureware, tubing sets, and other disposable products and supplies. The company provides its cell culture products and services to biopharmaceutical and biotechnology companies, medical schools, universities, research facilities, hospitals and public and private laboratories. Accentia Biopharmaceuticals, Inc. was founded in 2002 and is headquartered in Tampa, Florida.
accentia biopharmaceuticals (ABPI) Top Compensated Officers
accentia biopharmaceuticals (ABPI) Key Developments
On 05/15/2013, Accentia Biopharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
Effective on March 4, 2013, Accentia Biopharmaceuticals, Inc. and the Board of Directors accepted the retirement and resignation of Douglas W. Calder from his employment with the company, including Vice President, Strategic Planning & Capital Markets. Effective on March 4, 2013, the company’s Board of Directors accepted the retirement and resignation of Edmund C. King from his service to the company, including Director, Lead Director, audit committee financial expert, Chairman of the Audit Committee and his memberships on the Audit Committee, Compensation Committee and the Nominating and Governance Committee of the Board of Directors. Effective on March 5, 2013, the company and the company’s Board of Directors accepted the resignation of Christopher C. Chapman, M.D. from his service to the company including Director and his memberships on the Audit Committee, Compensation Committee and the Nominating and Governance Committee of the Board of Directors.
Accentia Biopharmaceuticals, Inc. announced the retirement and resignation of Samuel S. Duffey, Esq. from his employment with the company. Mr. Duffey’s retirement represents the resignation from all positions held by Mr. Duffey with the company, including President, Chief Executive Officer, Principal Executive Officer, and General Counsel. Garrison J. Hasara, C.P.A. was appointed to serve in the position of Acting Chief Executive Officer, along with his current positions as, Acting Chief Financial Officer, and Controller of the company. In addition, Mr. Hasara was also designated to serve as the company’s Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer in connection with dealings with the company’s independent audit firm and filings with the Securities and Exchange Commission.
| Recently Viewed | |||
| ABPI:US | $0.01 USD | +0.0005 |  |
| Company | Last | Change | |
| No competitor information is available for ABPI. | |||
| View Industry Companies | |||
Industry Analysis
ABPI
Industry Average
| Valuation | ABPI | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 0.3x |
|
| Price/Book | NM | Not Meaningful |
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | NM | Not Meaningful |
Post a JobJobs
- Chicago, IL | DunnhumbyusaPosted: Jun 18
- Thomasville, GA | Flowers FoodsPosted: Jun 07
- San Francisco, CA | YelpPosted: Jun 06
- San Francisco, CA | PeoplematterPosted: Jun 06
Sponsored Financial Commentaries
Sponsored Links
To contact ACCENTIA BIOPHARMACEUTICALS, please visit www.accentia.net. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.
